BERG Announces Presentation Of Multiple Interrogative Biology Platform And Outputs At AACR

By AIT News Desk On Jun 23, 2020

BERG, a clinical-stage biotech that employs artificial intelligence (AI) to research diseases and develop innovative treatments, announced five presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from June 22- 24, 2020.

Two presentations feature outputs of the BERG Interrogative Biology platform. One focuses on BERG’s Interrogative Biology discovered oncology target BPM 42522, its lead molecule, and mechanism of action leading to its anti-cancer properties. The other highlights validation of the BERG pan-cancer model by an independent study (Behan FM et al., (Nature, 2019 Apr 10). Three other presentations demonstrate the translational impact from current collaborations with institutions including BIDMC/Harvard, Stanford University and Uniformed Services University of the Health Sciencesalong with Walter Reed National Military Medical Center.

Web3 and AI Platform AGII Introduces Real-Time Anomaly Detection to Strengthen Security in Decentralized Systems

Nov 14, 2024

Multiverse Computing Launches Singularity Machine Learning Classification Function in IBM’s Qiskit Functions Catalog

Nov 14, 2024

BobiHealth Secures Patent Protection for Security Methods and Techniques for Its AI Technology Platform

Nov 14, 2024

Prev Next 1 of 40,385

“We are making significant advances with BERG’s Interrogative Biology platform, by partnering with several thought leaders in the field of oncology at the upcoming AACR meeting,” said Dr. Niven R. Narain, BERG Co-founder, President and Chief Executive Officer. “This week, we will present the preliminary results of a lead molecule that modulates BPM 42522, as a direct result from BERG’s platform as well. None of this would be possible without the continued support of our partners around the world.”

Recommended AI News: IntoPIX Releases The FastTICO-XS SDK V1.2.4 For NVIDIA GPU

“BERG’s pioneering work in analyzing large molecular datasets with Bayesian Artificial Intelligence for identification of therapeutic targets with high translational potential, clearly illustrates the impact of our work in improving drug discovery as well as the success rates of our developments,” said Professor Vikas P. Sukhatme, M.D., Sc.D., Dean of the Emory School of Medicine, Chief Academic Officer of Emory Healthcare, and a member of BERG’s Scientific Advisory Board.